医学
比例危险模型
危险系数
阶段(地层学)
肾细胞癌
肾切除术
队列
内科学
癌症
肿瘤科
疾病
置信区间
回顾性队列研究
外科
肾
古生物学
生物
作者
Karl H. Tully,Sebastian Berg,Marco Paciotti,Florian Janisch,Stephen W. Reese,Joachim Noldus,Shahrokh F. Shariat,Toni K. Choueiri,Guido Müller,Bradley A. McGregor,Steven L. Chang,Quoc‐Dien Trinh,Matthew Mossanen
标识
DOI:10.1016/j.clgc.2022.11.015
摘要
Sarcomatoid differentiation in patients diagnosed with renal cell carcinoma (sRCC) imply aggressive behavior and often metastatic disease at the time of diagnosis. We aim to examine the overall survival (OS) in patients with sRCC using the National Cancer Database (NCDB).We identified patients diagnosed with sRCC between 2010-2015. We employed Kaplan-Meier curves and multivariable Cox proportional hazards regression models to examine the impact of several potential risk factors on OS in patients diagnosed with sRCC.In total, 8582 patients with renal cancer were found to have sarcomatoid differentiation, with 4105 patients (47.8%) being diagnosed with AJCC stage IV disease. The median OS was 17.2 months (IQR 5.4, 68.7 months). Compared to patients who did not undergo surgery, OS was significantly longer in patients undergoing partial or total nephrectomy across all stages. This result remained consistent on multivariable Cox proportional hazards regression adjusting for patient and tumor characteristics (Surgery: Hazard ratio 0.54, 95%Confidence interval 0.43 - 0.68, P < .001).In our cohort sRCC was found to have an unfavorable median OS, which was mainly caused by the high number of cases diagnosed with late-stage disease. Additionally, surgery was associated with favorable OS across all stages. This study supports the notion that surgical therapy, even in the setting of cytoreductive surgery, provides a survival benefit in patients with sRCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI